Skip to main content
Fig. 8 | BMC Cancer

Fig. 8

From: KPT-330, a potent and selective exportin-1 (XPO-1) inhibitor, shows antitumor effects modulating the expression of cyclin D1 and survivin in prostate cancer models

Fig. 8

a Immunohistochemical evaluation of XPO-1, p53, Foxo3a and IkBa performed in 22rv1 xenografts treated with or without KPT-251 or KPT-330. In this fig. is shown XPO-1, p53, Foxo3a and IkBa expression to demonstrate the changes in nuclear expression and protein level induced by KPT-251 (100 mg/kg) and KPT-330 (10 mg/kg) treatments. b Changes in the expression of XPO-1 in PC3 xenografts treated with or without KPT-251 or KPT-330

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us